Simcyp Limited www.simcyp.com Experience as an SME involved in funded research Biocity Framework Focus Event, Nottingham, ...
<ul><li>Main activities  </li></ul><ul><ul><li>Population-based Simulator (M&S of PKPD virtual populations) </li></ul></ul...
<ul><li>2001 (The University of Sheffield) </li></ul><ul><ul><li>Professor Geoff  Tucker (Chairman) </li></ul></ul><ul><ul...
Simcyp – how is it used? <ul><li>Provide   Modelling and Simulation tools </li></ul><ul><ul><li>Examine pharmacokinetic be...
Simcyp – how is it used? <ul><li>Simcyp helps... </li></ul><ul><ul><li>Reduce and refine animal testing </li></ul></ul><ul...
Simcyp’s Grant History (2004 – 2007) <ul><ul><ul><li>2004 - 2010 ‘BIOSIM’ FP6  </li></ul></ul></ul><ul><ul><li>‘ Biosimula...
Simcyp’s Grant History (2008 – present) <ul><ul><ul><li>2008 - 2013 ‘PREDICT-IV’ FP7 </li></ul></ul></ul><ul><ul><li>‘ Pro...
Simcyp Grant History (2004 onwards)  FP6 , FP7, IMI 6 International Collaborative Projects € 1, 155, 099 since 2004
Key breaks: <ul><li>Early publications raised awareness </li></ul><ul><ul><li>Proctor et al , Xenobiotica 2004 ,  34 : 151...
Benefits / things to consider: <ul><li>Significant Benefits to Simcyp </li></ul><ul><ul><li>Scientific development to meet...
What have we learnt? <ul><li>Experience </li></ul><ul><ul><li>Understanding agreements / guidelines / eligibility / requir...
Points to emphasise in a proposal: <ul><li>Well established Consortium </li></ul><ul><ul><li>International collaboration  ...
Advice for SME’s looking to participate: <ul><li>CORDIS website valuable tool ( www.cordis.europa.eu/ )   </li></ul><ul><u...
THANK YOU Please contact me if you have any questions [email_address]
Upcoming SlideShare
Loading in …5
×

Simcyp Presentation - Rebecca Martell

1,178 views

Published on

Published in: Technology, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
1,178
On SlideShare
0
From Embeds
0
Number of Embeds
11
Actions
Shares
0
Downloads
25
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Simcyp Presentation - Rebecca Martell

  1. 1. Simcyp Limited www.simcyp.com Experience as an SME involved in funded research Biocity Framework Focus Event, Nottingham, May, 2011 Rebecca Martell, Grants Coordinator, Simcyp Limited [email_address]
  2. 2. <ul><li>Main activities </li></ul><ul><ul><li>Population-based Simulator (M&S of PKPD virtual populations) </li></ul></ul><ul><ul><li>Paediatric (PK behaviour in infants) </li></ul></ul><ul><ul><li>Animal (Compare data without allometric scaling) </li></ul></ul><ul><ul><li>Education programmes (workshops) </li></ul></ul><ul><ul><li>Practical training </li></ul></ul><ul><ul><li>Consultancy </li></ul></ul><ul><li>Active R&D team </li></ul><ul><ul><li>Publications, oral presentations, poster presentations </li></ul></ul>Simcyp Limited:
  3. 3. <ul><li>2001 (The University of Sheffield) </li></ul><ul><ul><li>Professor Geoff Tucker (Chairman) </li></ul></ul><ul><ul><li>Professor Amin Rostami-Hodjegan (Director of R&D) </li></ul></ul><ul><ul><li>Mr John Evans (Managing Director) </li></ul></ul><ul><li>EC SME definition </li></ul><ul><ul><li><250 employees (53 and growing), annual turnover < € 50 million </li></ul></ul><ul><li>Prestigious awards </li></ul><ul><ul><li>2010: ‘Queen’s Award For Enterprise’ </li></ul></ul><ul><ul><li>2009: ‘Outstanding Scientific Contribution to Animal Replacements’ </li></ul></ul>Simcyp Limited:
  4. 4. Simcyp – how is it used? <ul><li>Provide Modelling and Simulation tools </li></ul><ul><ul><li>Examine pharmacokinetic behaviour in virtual populations </li></ul></ul><ul><ul><li>Extreme clinical scenarios, safety of a computer </li></ul></ul><ul><li>Pharmaceutical companies, Simcyp consortium </li></ul><ul><ul><li>Consortium guide development, determine R&D priorities </li></ul></ul><ul><ul><li>Annual meeting </li></ul></ul><ul><ul><li>70% of top-40 pharmaceutical companies use Simcyp </li></ul></ul><ul><ul><li>Also used by regulatory bodies / universities </li></ul></ul><ul><li>Scientific Advisory Board </li></ul><ul><ul><li>Board of independent experts in field provide guidance </li></ul></ul>
  5. 5. Simcyp – how is it used? <ul><li>Simcyp helps... </li></ul><ul><ul><li>Reduce and refine animal testing </li></ul></ul><ul><ul><li>Enable more informed decisions </li></ul></ul><ul><ul><li>Assists development of safer medicines </li></ul></ul><ul><ul><li>Improve drug development process (time and costs) </li></ul></ul><ul><li>External citations </li></ul><ul><ul><li>External publications / presentations demonstrating application of Simcyp </li></ul></ul><ul><li>Strong Academic Links </li></ul><ul><ul><li>Used in teaching and research in academic centres of excellence </li></ul></ul>
  6. 6. Simcyp’s Grant History (2004 – 2007) <ul><ul><ul><li>2004 - 2010 ‘BIOSIM’ FP6 </li></ul></ul></ul><ul><ul><li>‘ Biosimulation – a new tool in drug development’ </li></ul></ul><ul><ul><li>In silico M&S tools to reduce time / costs of developing new drugs and animal experiments </li></ul></ul><ul><ul><li>Results: successful, wide dissemination, PhD students trained, collaborations with healthcare / regulatory agencies </li></ul></ul><ul><ul><ul><li>2007 - 2010 ‘LIINTOP’ FP7 </li></ul></ul></ul><ul><ul><li>‘ Optimisation of liver and intestine in vitro model for pharmacokinetic and pharmacodynamic studies’ </li></ul></ul><ul><ul><li>In vitro tests to replace animal experiments </li></ul></ul><ul><ul><li>Results: successful, wide dissemination, objectives achieved </li></ul></ul>
  7. 7. Simcyp’s Grant History (2008 – present) <ul><ul><ul><li>2008 - 2013 ‘PREDICT-IV’ FP7 </li></ul></ul></ul><ul><ul><li>‘ Profiling the toxicity of new drugs: a non animal-based approach integrating toxico-dynamics and biokinetics’ </li></ul></ul><ul><ul><li>Safety assessment for early drug development / late discovery </li></ul></ul><ul><ul><ul><li>2010 - 2013 ‘NEUROBID’ FP7 </li></ul></ul></ul><ul><ul><li>‘ Neuroscience on barriers in development’ </li></ul></ul><ul><ul><li>Understanding BBB in the developing brain and neurological disorders in infancy </li></ul></ul><ul><ul><ul><li>2011 - 2016 ‘TINN2’ FP7 </li></ul></ul></ul><ul><ul><li>‘ Treat infections in neonates 2’ </li></ul></ul><ul><ul><li>Evaluate azithromycin to treat infections in preterm's / neonates </li></ul></ul><ul><ul><ul><li>2011 - 2016 ‘DDMoRe’ IMI </li></ul></ul></ul><ul><ul><li>‘ Drug Disease Model Resources’ </li></ul></ul><ul><ul><li>Common language for data / models / workflows </li></ul></ul>
  8. 8. Simcyp Grant History (2004 onwards) FP6 , FP7, IMI 6 International Collaborative Projects € 1, 155, 099 since 2004
  9. 9. Key breaks: <ul><li>Early publications raised awareness </li></ul><ul><ul><li>Proctor et al , Xenobiotica 2004 , 34 : 151 -178. </li></ul></ul><ul><ul><li>Rostami et al , Drug Discovery Today: Technologies 2004 , 1 : 441 – 448 </li></ul></ul><ul><li>Active R&D team (the key!) </li></ul><ul><ul><li>Present at international conferences on range of topics, all scientists involved </li></ul></ul><ul><ul><li>Simcyp approached to participate in BioSim after a EUFEPS presentation </li></ul></ul><ul><li>Recommendations </li></ul><ul><ul><li>Recommended by others (SAB) </li></ul></ul><ul><li>All demonstrates application of Simcyp to opinion leaders! </li></ul>
  10. 10. Benefits / things to consider: <ul><li>Significant Benefits to Simcyp </li></ul><ul><ul><li>Scientific development to meet industry needs </li></ul></ul><ul><ul><li>Basis for future collaboration </li></ul></ul><ul><ul><li>Demonstrate application / utilisation of Simcyp & expands team! </li></ul></ul><ul><li>Things we have learnt to consider </li></ul><ul><ul><li>Administrative effort (proposal, timesheets, reports, emails, meetings...) </li></ul></ul><ul><ul><li>75% of costs covered, need ‘strategic fit’ to company </li></ul></ul><ul><ul><li>Agreement clauses, particularly IPR for SME’s </li></ul></ul><ul><ul><li>Partner / Coordinator - what suits your company </li></ul></ul><ul><ul><li>Achievable deliverables, reporting thoroughly checked! </li></ul></ul>
  11. 11. What have we learnt? <ul><li>Experience </li></ul><ul><ul><li>Understanding agreements / guidelines / eligibility / requirements </li></ul></ul><ul><ul><li>Awareness of resources involved, can plan </li></ul></ul><ul><ul><li>But things change, it’s a learning process </li></ul></ul><ul><ul><li>Early communication on possible projects crucial </li></ul></ul><ul><li>Dedicated person </li></ul><ul><ul><li>Joined company in 2008, appointed to role 2010 </li></ul></ul><ul><ul><li>Prior to appointment, submitted full ERA-NET proposal </li></ul></ul><ul><ul><li>Don’t conduct research but work closely with R&D team </li></ul></ul><ul><ul><li>Involved in full process (from research new grants to managing existing ones) </li></ul></ul>
  12. 12. Points to emphasise in a proposal: <ul><li>Well established Consortium </li></ul><ul><ul><li>International collaboration / strength / previous collaboration / coordination / management </li></ul></ul><ul><ul><li>Expertise of Consortium members </li></ul></ul><ul><li>Scientific points </li></ul><ul><ul><li>Relation to EC topic call </li></ul></ul><ul><ul><li>Achievement of deliverables / objectives </li></ul></ul><ul><ul><li>Knowledge gaps addressed </li></ul></ul><ul><li>Dissemination </li></ul><ul><ul><li>Management of IP </li></ul></ul><ul><ul><li>SME’s significantly contribute to dissemination / impact </li></ul></ul>
  13. 13. Advice for SME’s looking to participate: <ul><li>CORDIS website valuable tool ( www.cordis.europa.eu/ ) </li></ul><ul><ul><li>Grant and Consortium agreements </li></ul></ul><ul><ul><li>Intellectual property rights and negotiation guidelines </li></ul></ul><ul><ul><li>Help desk for enquiries </li></ul></ul><ul><ul><li>Partner search </li></ul></ul><ul><ul><li>Utilise existing networks </li></ul></ul><ul><li>National Contact Points </li></ul><ul><ul><li>Provide individual advice and assistance (list on CORDIS) </li></ul></ul><ul><li>Courses </li></ul><ul><ul><li>‘ FP7 Consortium Agreements’, ‘Coordinating FP7 Research Projects’ ( http://www.singleimage.co.uk/ ) </li></ul></ul>
  14. 14. THANK YOU Please contact me if you have any questions [email_address]

×